NanoFUSE DBM is the company’s proprietary bone void filler product. Specifically, it has been cleared for use with autograft as a bone graft extender in the posterolateral spine. It is the first off-the-shelf DBM product containing bioactive glass available for use in an orthopedic clinical setting.
More articles on devices:
Amedica brings on with PCG Advisory as agency of record
OrthoWorx commits $475k on workforce development — 6 initiatives
Mesoblast gets patent for mesenchymal precursor cell technology — 7 thing to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
